Anixa Biosciences (ANIX) said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.
The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.
The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.
Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.
Shares of Anixa were up more than 3% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.